Literature DB >> 11220635

Molecular cloning of CS1, a novel human natural killer cell receptor belonging to the CD2 subset of the immunoglobulin superfamily.

K S Boles1, P A Mathew.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11220635     DOI： 10.1007/s002510000274

Source DB:  PubMed          Journal:  Immunogenetics        ISSN： 0093-7711            Impact factor:   2.846


× No keyword cloud information.
  21 in total

1.  A novel immunogenic CS1-specific peptide inducing antigen-specific cytotoxic T lymphocytes targeting multiple myeloma.

Authors:  Jooeun Bae; Weihua Song; Robert Smith; John Daley; Yu-Tzu Tai; Kenneth C Anderson; Nikhil C Munshi
Journal:  Br J Haematol       Date:  2012-04-26       Impact factor: 6.998

2.  Alternative splicing and mRNA expression analysis of bovine SLAMF7 gene in healthy and mastitis mammary tissues.

Authors:  Zhihua Ju; Changfa Wang; Qiuling Li; Minghai Hou; Shuai Gao; Qinlei Hou; Jianbin Li; Jinming Huang; Jifeng Zhong
Journal:  Mol Biol Rep       Date:  2011-07-17       Impact factor: 2.316

Review 3.  CS1 (SLAMF7, CD319) is an effective immunotherapeutic target for multiple myeloma.

Authors:  Joseph D Malaer; Porunelloor A Mathew
Journal:  Am J Cancer Res       Date:  2017-08-01       Impact factor: 6.166

4.  CS1, a potential new therapeutic antibody target for the treatment of multiple myeloma.

Authors:  Eric D Hsi; Roxanne Steinle; Balaji Balasa; Susann Szmania; Aparna Draksharapu; Benny P Shum; Mahrukh Huseni; David Powers; Amulya Nanisetti; Yin Zhang; Audie G Rice; Anne van Abbema; Melanie Wong; Gao Liu; Fenghuang Zhan; Myles Dillon; Shihao Chen; Susan Rhodes; Franklin Fuh; Naoya Tsurushita; Shankar Kumar; Vladimir Vexler; John D Shaughnessy; Bart Barlogie; Frits van Rhee; Mohamad Hussein; Daniel E H Afar; Marna B Williams
Journal:  Clin Cancer Res       Date:  2008-05-01       Impact factor: 12.531

Review 5.  Immunotherapy for Multiple Myeloma, Past, Present, and Future: Monoclonal Antibodies, Vaccines, and Cellular Therapies.

Authors:  Rebecca Karp Leaf; Hearn Jay Cho; David Avigan
Journal:  Curr Hematol Malig Rep       Date:  2015-12       Impact factor: 3.952

6.  Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu.

Authors:  Yu-Tzu Tai; Myles Dillon; Weihua Song; Merav Leiba; Xian-Feng Li; Peter Burger; Alfred I Lee; Klaus Podar; Teru Hideshima; Audie G Rice; Anne van Abbema; Lynne Jesaitis; Ingrid Caras; Debbie Law; Edie Weller; Wanling Xie; Paul Richardson; Nikhil C Munshi; Claire Mathiot; Hervé Avet-Loiseau; Daniel E H Afar; Kenneth C Anderson
Journal:  Blood       Date:  2007-09-28       Impact factor: 22.113

Review 7.  CAR T cell therapies for patients with multiple myeloma.

Authors:  Lekha Mikkilineni; James N Kochenderfer
Journal:  Nat Rev Clin Oncol       Date:  2020-09-25       Impact factor: 66.675

Review 8.  Current advances in chimeric antigen receptor T-cell therapy for refractory/relapsed multiple myeloma.

Authors:  He Huang; Heng-Wei Wu; Yong-Xian Hu
Journal:  J Zhejiang Univ Sci B       Date:  2020 Jan.       Impact factor: 3.066

9.  CS1 promotes multiple myeloma cell adhesion, clonogenic growth, and tumorigenicity via c-maf-mediated interactions with bone marrow stromal cells.

Authors:  Yu-Tzu Tai; Ender Soydan; Weihua Song; Mariateresa Fulciniti; Kihyun Kim; Fangxin Hong; Xian-Feng Li; Peter Burger; Matthew J Rumizen; Sabikun Nahar; Klaus Podar; Teru Hideshima; Nikhil C Munshi; Giovanni Tonon; Ruben D Carrasco; Daniel E H Afar; Kenneth C Anderson
Journal:  Blood       Date:  2009-02-04       Impact factor: 22.113

10.  CS1 (SLAMF7) inhibits production of proinflammatory cytokines by activated monocytes.

Authors:  Jong R Kim; Nathan C Horton; Stephen O Mathew; Porunelloor A Mathew
Journal:  Inflamm Res       Date:  2013-05-22       Impact factor: 4.575
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.